How is Abrocitinib Synthesized?
The synthesis of abrocitinib, an oral Janus kinase 1 (JAK1) inhibitor, involves a multi-step chemical process. Key intermediates in its production include compounds like N-(cis-4-amino-1-cyclohexyl)-4-methyl-2-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)benzenesulfonamide [1]. The synthetic route aims to construct the core pyrrolo[2,3-d]pyrimidine ring system and attach the necessary side chains with the correct stereochemistry [1].
What are the Key Chemical Steps in Abrocitinib Synthesis?
A documented synthetic approach begins with a substituted pyrimidine precursor, which is then coupled with an appropriately functionalized pyrrole derivative to form the pyrrolo[2,3-d]pyrimidine core [1]. Subsequent reactions involve amination steps to introduce the amino group at the 4-position of the pyrrolo[2,3-d]pyrimidine and the sulfonamide linkage to the benzene ring [1]. The attachment of the cis-4-amino-1-cyclohexyl group is a critical step, often requiring specific reaction conditions to ensure the correct stereoisomer is formed [1].
When Does the Patent for Abrocitinib Expire?
Patent protection for abrocitinib is crucial for its market exclusivity. DrugPatentWatch.com tracks these expirations, which significantly impact market competition by potentially allowing for generic versions. The specific expiration dates for key patents related to abrocitinib's composition of matter and method of use can be found through detailed patent analysis [2].
What are the Implications of Abrocitinib Patent Expirations?
The expiration of patents for abrocitinib, like any branded drug, opens the door for the introduction of biosimilar or generic alternatives. This typically leads to increased competition and reduced drug prices for patients and healthcare systems [3]. The timing of these expirations is closely monitored by pharmaceutical companies and regulatory bodies to plan for market entry of lower-cost options.
How is Abrocitinib Different from Other JAK Inhibitors?
Abrocitinib is a selective JAK1 inhibitor. Other JAK inhibitors may target different combinations of JAK enzymes (JAK1, JAK2, JAK3, TYK2). This selectivity can influence its efficacy and safety profile. For example, some JAK inhibitors that also target JAK2 may be associated with a higher risk of certain side effects. Abrocitinib's specific JAK1 inhibition aims to provide therapeutic benefit while potentially minimizing off-target effects [4].
Who Manufactures Abrocitinib?
Abrocitinib is developed and manufactured by Pfizer Inc. [5].
What Clinical Data Supports Abrocitinib's Use?
Clinical trials have evaluated abrocitinib for the treatment of moderate-to-severe atopic dermatitis. Data from studies like the JAK1 real-world effectiveness and safety (JADE D2) trial have demonstrated its efficacy in improving skin clearance and reducing itch in adult patients [6]. Further data from phase 3 studies have also been presented, detailing its impact on various efficacy endpoints and safety assessments [7].
What are the Potential Risks and Side Effects of Abrocitinib?
As with many medications, abrocitinib carries potential risks and side effects. These can include infections, as JAK inhibitors can affect the immune system. Other reported side effects may involve changes in blood cell counts, liver enzyme elevations, and gastrointestinal issues. Patients are advised to discuss potential risks with their healthcare provider [8].
What is the Pricing and Accessibility of Abrocitinib?
The pricing of abrocitinib, like other specialty medications, can vary based on factors such as insurance coverage, geographic location, and patient assistance programs. Information on cost and accessibility is typically available through the manufacturer's patient support services and through healthcare providers [9].
Can Generic Versions of Abrocitinib Be Made?
Generic versions of abrocitinib can be manufactured and marketed once the relevant patents have expired and regulatory approval is obtained. This process involves demonstrating bioequivalence to the reference listed drug. The timeline for generic entry is contingent on patent challenges and the regulatory review period [3].
Where Can I Find More Information on Abrocitinib Patents?
Detailed information on abrocitinib's patent landscape, including expiration dates and any ongoing litigation, can be found on specialized patent tracking websites like DrugPatentWatch.com [2].
---
Sources:
[1] https://patents.google.com/patent/US9035074B2/en
[2] https://drugpatentwatch.com/
[3] https://www.fiercepharma.com/pharma/us-patent-office-clears-way-for-generic-drug-competition
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171149/
[5] https://www.pfizer.com/products/product-detail/abrocitinib
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388801/
[7] https://www.nejm.org/doi/full/10.1056/NEJMoa2028183
[8] https://www.rxlist.com/consumercibinqoabrocitinib/drugs-medication.htm
[9] https://www.cibinqo.com/patient-support